Novartis Korea Attains New Indication for Diovan

Novartis Korea announced that it has received an approval by the Korea Food and Drug Administration (KFDA) on the additional indication for Diovan (active ingredient: valsartan) as a first-line, post MI (myocardial infarction) treatment in high-risk patients.

Diovan, a highly selective angiotensin II receptor blocker (ARB) marketed by Novartis Korea, is already approved for the treatment of ...